ClinicalTrials.gg
CompletedNCT01746095Updated Jan 13, 2020Results posted

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

A Phase 2 interventional study of Vancomycin hydrochloride inhalation powder and Placebo inhalation powder in Cystic Fibrosis, sponsored by Savara Inc.. Completed at 38 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-01-13.

Sponsored by Savara Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 717 studies in Cystic Fibrosis with a site in United States — 86 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Enrollment
136th of 517
87 · median 36
Started
2013
with 36 others
Phase 2
103 of 717
10 open now
Registered
265th of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 136th largest by enrollment of the 517 interventional ones that give a count, is one of 37 that started in 2013, is one of 103 in phase 2, and was the 265th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

86 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

81 more — sign in →

All 86 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether AeroVanc treatment is safe and effective in reducing the number of MRSA colony forming units in the lungs of cystic fibrosis patients.

Read the detailed description

This is a Phase 2a randomized, multicenter, double-blind, placebo-controlled, parallel group study to examine the safety and efficacy of AeroVanc in the treatment of persistent MRSA lung infection in CF patients. Pharmacokinetics will be evaluated in a subgroup by measuring plasma and sputum concentrations of vancomycin.

Prior to treatment, patients will be randomized to receive either AeroVanc twice daily (bid), or placebo bid. Patients will be stratified based on the presence of a Pseudomonas aeruginosa (P. aeruginosa) co-infection that is being treated with a chronic suppression regimen. Patients with P. aeruginosa co-infection can be on any chronic inhaled suppression regimen (or nothing if the patient is considered stable in the opinion of the investigator despite the lack of treatment). Regardless of treatment regimen, if there is an off month, screening should be scheduled so that AeroVanc or placebo administration can be given during this time. Patients with no off month should be screened so that the AeroVanc or placebo administration period coincides with a treatment cycle other than TOBI (e.g., Cayston or colistin). All patients must have at least a 24-hour washout period after stopping their anti-Pseudomonas therapy and prior to the Visit 2 (Baseline) pre-dose microbiology sputum sample. The AeroVanc or placebo treatment duration is 28 days, during which efficacy and safety parameters will be measured, and after which patients will be followed up for 56 days.

There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to placebo) and treated patients (adults ≥18 and children ≥12 years of age). In Cohort 1, patients will be enrolled and randomized to receive the 32 mg dose of AeroVanc bid or placebo bid. Prior to starting enrollment in Cohort 2, a safety evaluation will be carried out by the Data Monitoring Committee (DMC) based on treatment data from the first 20 patients in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg bid. Optionally, the active arm for Cohort 2 may also be kept the same (32 mg bid), or reduced to 16 mg bid, depending on the outcome of the DMC's safety evaluation.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

Keywords

  • Cystic Fibrosis
  • MRSA
  • Methicillin-resistant Staphylococcus aureus
  • Lung infection
  • AeroVanc
  • Vancomycin
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults ≥18 years old (and the legally authorized representatives of children ≥12 but \<18 years old): Able to communicate with site personnel and to understand and voluntarily sign the Form (ICF). Children ≥12 but \<18 years old: Able to communicate with site personnel and to understand and voluntarily sign the Assent Form.
  2. Able and willing to comply with the protocol, including availability for all scheduled study visits.
  3. Have a confirmed diagnosis of CF, determined by having clinical features consistent with the CF phenotype, plus one of the following: a) Positive sweat chloride test (value ≥60 mEq/L), or b) Genotype with two mutations consistent with CF (ie, a mutation in each of the cystic fibrosis transmembrane conductance regulator [CFTR] genes).
  4. Be ≥12 years old at time of ICF/Assent Form signing.
  5. Have sputum culture positive for MRSA at Screening, with at least 10,000 CFUs/mL of MRSA.
  6. In addition to the screening sample, have at least two historical respiratory tract cultures (i.e., sputum and/or throat swab) positive for MRSA prior to Screening and evidence that the MRSA lung infection has persisted for at least 6 months prior to Screening.
  7. Have (FEV1) ≥30% and ≤100% of predicted that is normalized for age, gender, and height at Screening.
  8. Evidence, defined as one or both of the following, that the persistent MRSA lung infection is suspected to be causing health consequences.

    • Have had at least one episode of acute pulmonary infection treated with non-maintenance antibiotics within 12 months from Screening. Initiation of treatment with intermittent inhaled anti-Pseudomonas therapy will not qualify as treatment with non-maintenance antibiotics.
    • Requires anti-MRSA treatment as part of a maintenance regimen to prevent pulmonary exacerbations or other respiratory symptoms.
  9. Be able to perform all the techniques necessary to use the AeroVanc inhaler and measure lung function.
  10. Be able to produce expectorated sputum samples or be able and willing to undergo standardized sputum induction.
  11. Agree not to smoke from Screening through the end of the study.
  12. Female patients of are eligible to participate in this study only if they are NOT pregnant or lactating, and if the patient is using a highly effective method of .
  13. Patients with P. aeruginosa co-infection must either be stable on a regular suppression regimen of inhaled antibiotics or must be, in the opinion of the investigator, stable despite the lack of such treatment. Patients on a Cayston based therapy must have received at least 2 cycles of Cayston prior to Baseline (can be 2 consecutive months or 2 cycles over 4 months).

Exclusion criteria

Exclusion Criteria:

  1. Administration of any drug or device within 28 days prior to ICF/Assent Form signing.
  2. Use of iv or inhaled anti-MRSA drugs within 28 days or oral anti-MRSA drugs within 14 days prior to Visit 2 (ie, randomization, Baseline and AeroVanc/placebo treatment initiation).
  3. A history of previous allergies or sensitivity to vancomycin, or other component(s) of the study drug or placebo except for a history of red-man syndrome.
  4. History of severe cough/bronchospasm upon inhalation of dry powder inhalation product, or nebulized vancomycin.
  5. Resistance to vancomycin at Screening (vancomycin resistant Staphylococcus aureus [VRSA], or vancomycin intermediate resistant Staphylococcus aureus [VISA], with minimum inhibitory concentration [MIC] ≥4 mcg/mL).
  6. Oral in doses exceeding 10 mg prednisone per day or 20 mg prednisone every other day, or equipotent doses of another corticosteroid.
  7. History of sputum culture or throat swab culture yielding B. cepacia or gladioli in the previous two years, or nontuberculosis mycobacteria in the previous six months.
  8. An acute upper or lower respiratory infection, or pulmonary exacerbation within 7 days prior to Randomization.
  9. Changes in antimicrobial, bronchodilator, anti-inflammatory or corticosteroid medications within 7 days prior to ICF/Assent Form signing.
  10. Current daily continuous oxygen supplementation or requirement for more than 2 L/min at night.
  11. Changes in physiotherapy technique or schedule within 7 days prior to ICF/Assent Form signing.
  12. History of lung or other solid organ transplantation or currently on the list to receive lung or other solid organ transplantation.
  13. A chest X-Ray at Screening with abnormalities indicating a significant acute finding (eg, pneumothorax, or pleural effusion).
  14. Lactating female or female with a positive pregnancy test result. All women of will be tested.
  15. Renal insufficiency, defined as \<50 mL/min using the Cockcroft-Gault equation for adults or Schwartz equation in children, at Screening.
  16. Diagnosed with hearing loss.
  17. Abnormal liver function, defined as ≥4x (ULN), of serum (AST) or serum alanine aminotransferase (ALT), or known cirrhosis at the time of Screening.
  18. Serum hematology or chemistry screening results which in the judgment of the Investigator would interfere with completion of the study.
  19. Positive for (HIV), virus (HBV) or virus (HCV).
  20. Other findings or medical history at screening that, in the Investigator's opinion, would compromise the safety of the patient or the quality of the study data.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Vancomycin hydrochloride inhalation powder

    32 or 64 mg twice daily (BID)

    Drug: Vancomycin hydrochloride inhalation powder

  • Placebo comparator
    Placebo inhalation powder

    Matching placebo inhalation powder BID

    Drug: Placebo inhalation powder

Interventions

  • DrugVancomycin hydrochloride inhalation powder

    There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to placebo) and treated patients (adults ≥18 and children ≥12 years of age). In Cohort 1, patients will be enrolled and randomized to receive the 32 mg dose of AeroVanc bid or placebo bid. Prior to starting enrollment in Cohort 2, a safety evaluation will be carried out by the Data Monitoring Committee (DMC) based on treatment data from the first 20 patients in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg bid. Optionally, the active arm for Cohort 2 may also be kept the same (32 mg bid), or reduced to 16 mg bid, depending on the outcome of the DMC's safety evaluation.

    Also known as: AeroVanc

  • DrugPlacebo inhalation powder
06

What researchers measure

Primary outcomes

  1. Change From Baseline in MRSA Sputum Density.

    Change from Baseline at Day 29 of the dosing period (start of AeroVanc/Placebo administration is considered Day 1 of the dosing period) in the number of MRSA colony forming units (CFU) in sputum culture.

    Time frame: Day 29 of treatment period

Secondary outcomes

  1. Change From Baseline in MRSA Sputum Density.

    Time frame: Day 8 of treatment period

  2. Change From Baseline in MRSA Sputum Density.

    Time frame: Day 15 of treatment period

  3. Change From Baseline in FEV1

    Absolute change from baseline in FEV1 percent predicted

    Time frame: Day 29 of treatment period

  4. Change From Baseline in FVC

    Absolute change from baseline in FVC percent predicted

    Time frame: Day 29 of treatment period

  5. Change From Baseline in Cystic Fibrosis Respiratory Symptom Diary (CFRSD-CRISS) Scores

    Change from Baseline in Cystic Fibrosis Respiratory Symptom Diary (CFRSD) Chronic Respiratory Infection Symptom Scores (CRISS). The minimum score is 0 and the maximum is 100, where a higher score means a worse outcome.

    Time frame: Day 29 of treatment period

  6. Time From Start of Dosing to First Administration of Other Antimicrobial Medications (Oral, Intravenous and/or Inhaled) Due to Respiratory Symptoms.

    Time frame: Entire study: Day 1 of treatment period through 8 week post-treatment follow up visit

  7. Time From Start of Dosing to Exacerbation of Signs/Symptoms (Fuchs Criteria).

    Time frame: Entire study: Day 1 of treatment period through 8 week post-treatment follow up visit

  8. Change From Baseline in High Sensitivity CRP

    Time frame: Day 29 of the dosing period

  9. Change From Baseline in Blood Neutrophils

    Time frame: Day 29 of the dosing period

07

Results

Posted Jan 13, 2020

Participant flow

Participant flow — Overall Study
MilestoneAeroVanc 32 mgPlacebo to 32 mgAeroVanc 64 mgPlacebo to 64 mg
Started20202423
Completed16161115
Not completed44138

Outcome measures

PrimaryChange From Baseline in MRSA Sputum Density.

Change from Baseline at Day 29 of the dosing period (start of AeroVanc/Placebo administration is considered Day 1 of the dosing period) in the number of MRSA colony forming units (CFU) in sputum culture.

Time frame:
Day 29 of treatment period
Reported as:
Least squares mean · Log10 CFU/mL
Change From Baseline in MRSA Sputum Density.
Log10 CFU/mLAeroVanc 32 mgPlacebo to 32 mgAeroVanc 64 mgPlacebo to 64 mg
Change From Baseline in MRSA Sputum Density.-0.25 ± 0.181-0.30 ± 0.182-0.63 ± 0.2320.16 ± 0.201
SecondaryChange From Baseline in MRSA Sputum Density.
Time frame:
Day 8 of treatment period
Reported as:
Least squares mean · Log10 CFU/mL
Change From Baseline in MRSA Sputum Density.
Log10 CFU/mLAeroVanc 32 mgPlacebo to 32 mgAeroVanc 64 mgPlacebo to 64 mg
Change From Baseline in MRSA Sputum Density.-0.27 ± 0.208-0.28 ± 0.223-1.04 ± 0.1930.08 ± 0.200
SecondaryChange From Baseline in MRSA Sputum Density.
Time frame:
Day 15 of treatment period
Reported as:
Least squares mean · Log10 CFU/mL
Change From Baseline in MRSA Sputum Density.
Log10 CFU/mLAeroVanc 32 mgPlacebo to 32 mgAeroVanc 64 mgPlacebo to 64 mg
Change From Baseline in MRSA Sputum Density.-0.55 ± 0.2590.09 ± 0.279-1.14 ± 0.2290.26 ± 0.216
SecondaryChange From Baseline in FEV1

Absolute change from baseline in FEV1 percent predicted

Time frame:
Day 29 of treatment period
Reported as:
Least squares mean · percentage of predicted FEV1
Change From Baseline in FEV1
percentage of predicted FEV1AeroVanc 32 mgPlacebo to 32 mgAeroVanc 64 mgPlacebo to 64 mg
Change From Baseline in FEV10.53 ± 1.3431.15 ± 1.356-0.68 ± 1.1449-2.61 ± 1.314
SecondaryChange From Baseline in FVC

Absolute change from baseline in FVC percent predicted

Time frame:
Day 29 of treatment period
Reported as:
Least squares mean · percentage of predicted FVC
Change From Baseline in FVC
percentage of predicted FVCAeroVanc 32 mgPlacebo to 32 mgAeroVanc 64 mgPlacebo to 64 mg
Change From Baseline in FVC-0.07 ± 1.2731.67 ± 1.283-0.47 ± 1.594-2.48 ± 1.423
SecondaryChange From Baseline in Cystic Fibrosis Respiratory Symptom Diary (CFRSD-CRISS) Scores

Change from Baseline in Cystic Fibrosis Respiratory Symptom Diary (CFRSD) Chronic Respiratory Infection Symptom Scores (CRISS). The minimum score is 0 and the maximum is 100, where a higher score means a worse outcome.

Time frame:
Day 29 of treatment period
Reported as:
Least squares mean · score on a scale
Change From Baseline in Cystic Fibrosis Respiratory Symptom Diary (CFRSD-CRISS) Scores
score on a scaleAeroVanc 32 mgPlacebo to 32 mgAeroVanc 64 mgPlacebo to 64 mg
Change From Baseline in Cystic Fibrosis Respiratory Symptom Diary (CFRSD-CRISS) Scores-6.59 ± 2.620-3.02 ± 2.614-0.55 ± 2.701-5.43 ± 2.552
SecondaryTime From Start of Dosing to First Administration of Other Antimicrobial Medications (Oral, Intravenous and/or Inhaled) Due to Respiratory Symptoms.
Time frame:
Entire study: Day 1 of treatment period through 8 week post-treatment follow up visit
Reported as:
Median · days
Time From Start of Dosing to First Administration of Other Antimicrobial Medications (Oral, Intravenous and/or Inhaled) Due to Respiratory Symptoms.
daysAeroVanc 32 mgPlacebo to 32 mgAeroVanc 64 mgPlacebo to 64 mg
Time From Start of Dosing to First Administration of Other Antimicrobial Medications (Oral, Intravenous and/or Inhaled) Due to Respiratory Symptoms.69.5 (34.0 to 107.0)80.0 (23.0 to NA)48.0 (14.0 to 66.0)NA (43.0 to NA)
SecondaryTime From Start of Dosing to Exacerbation of Signs/Symptoms (Fuchs Criteria).
Time frame:
Entire study: Day 1 of treatment period through 8 week post-treatment follow up visit
Reported as:
Median · days
Time From Start of Dosing to Exacerbation of Signs/Symptoms (Fuchs Criteria).
daysAeroVanc 32 mgPlacebo to 32 mgAeroVanc 64 mgPlacebo to 64 mg
Time From Start of Dosing to Exacerbation of Signs/Symptoms (Fuchs Criteria).107.0 (13.0 to 107.0)NA (13.0 to NA)49.0 (14.0 to 84.0)NA (37.0 to NA)
SecondaryChange From Baseline in High Sensitivity CRP
Time frame:
Day 29 of the dosing period
Reported as:
Least squares mean · mg/dL
Change From Baseline in High Sensitivity CRP
mg/dLAeroVanc 32 mgPlacebo to 32 mgAeroVanc 64 mgPlacebo to 64 mg
Change From Baseline in High Sensitivity CRP-0.34 ± 0.132-0.18 ± 0.1300.15 ± 0.223-0.09 ± 0.184
SecondaryChange From Baseline in Blood Neutrophils
Time frame:
Day 29 of the dosing period
Reported as:
Least squares mean · 10^9 cells/L
Change From Baseline in Blood Neutrophils
10^9 cells/LAeroVanc 32 mgPlacebo to 32 mgAeroVanc 64 mgPlacebo to 64 mg
Change From Baseline in Blood Neutrophils0.20 ± 0.5691.23 ± 0.561-0.29 ± 0.5570.04 ± 0.487

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AeroVanc 32 mg0/20 (0%)4/20 (20%)18/20 (90%)
Placebo to 32 mg0/20 (0%)2/20 (10%)18/20 (90%)
AeroVanc 64 mg0/24 (0%)1/24 (4.2%)20/24 (83.3%)
Placebo to 64 mg0/23 (0%)4/23 (17.4%)19/23 (82.6%)
Most frequent serious events
Most frequent serious events
EventAeroVanc 32 mgPlacebo to 32 mgAeroVanc 64 mgPlacebo to 64 mg
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations3/202/201/243/23
HyperglycemiaMetabolism and nutrition disorders1/200/200/240/23
PainGeneral disorders1/200/200/240/23
Infective exacerbation of bronchiectasisInfections and infestations1/200/200/240/23
PneumoniaInfections and infestations0/200/200/241/23
Pleural effusionRespiratory, thoracic and mediastinal disorders0/200/200/241/23
Most frequent other events
Showing 10 of 44
Most frequent other events
EventAeroVanc 32 mgPlacebo to 32 mgAeroVanc 64 mgPlacebo to 64 mg
CoughRespiratory, thoracic and mediastinal disorders9/207/209/2410/23
Respiratory tract congestionRespiratory, thoracic and mediastinal disorders8/204/207/247/23
Sputum increasedRespiratory, thoracic and mediastinal disorders6/207/206/245/23
FatigueGeneral disorders5/204/208/243/23
Paranasal sinus hypersecretionRespiratory, thoracic and mediastinal disorders6/203/204/241/23
Exercise tolerance decreasedGeneral disorders5/201/202/242/23
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations3/205/205/242/23
Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders4/202/205/243/23
Forced expiratory volume decreasedInvestigations4/202/203/241/23
Weight decreasedInvestigations4/201/202/241/23

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AeroVanc 32 mgPlacebo to 32 mgAeroVanc 64 mgPlacebo to 64 mgTotal
<=18 years764421
Between 18 and 65 years1314201966
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)AeroVanc 32 mgPlacebo to 32 mgAeroVanc 64 mgPlacebo to 64 mgTotal
Female1399839
Male711151548
Region of Enrollment
Region of Enrollment(participants)AeroVanc 32 mgPlacebo to 32 mgAeroVanc 64 mgPlacebo to 64 mgTotal
United States2020242387
08

Study locations

38 sites
  • Pulmonary Associates of Mobile
    Mobile, Alabama 36608, United States
  • University of Arkansas for Medical Science
    Little Rock, Arkansas 72205, United States
  • Children's Hospital Los Angeles, Division of Pediatric Pulmonology
    Los Angeles, California 90027, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Joe DiMaggio Children's Hospital
    Hollywood, Florida 33021, United States
  • University of Miami - Miller School of Medicine
    Miami, Florida 33136, United States
  • Central Florida Pulmonary Group
    Orlando, Florida 32803, United States
  • Nemours Children's Clinic and Hospital
    Orlando, Florida 32806, United States
  • New Lung Associates, PA; Lung Transplant, Adult Cystic Fibrosis, and the Center for Advanced Lung Diseases, Tampa General Hospital
    Tampa, Florida 33606, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • The Cystic Fibrosis Center of Chicago
    Glenview, Illinois 60025, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Kentucky Cystic Fibrosis Clinic
    Lexington, Kentucky 40536, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Massachusetts General Hospital Pediatric Cystic Fibrosis Center
    Boston, Massachusetts 02114, United States
  • Boston Children's Hospital Cystic Fibrosis Center
    Boston, Massachusetts 02115, United States
  • Wayne State University, Harper Hospital, Children's Hospital of Michigan
    Detroit, Michigan 48201, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Rutgers Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901, United States
  • Hofstra North Shore - Long Island Jewish School of Medicine
    New Hyde Park, New York 11040, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Rainbow Babies and Children's Hospital / University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • The Children's Medical Center of Dayton
    Dayton, Ohio 45404, United States
  • Santiago Reyes, MD
    Oklahoma City, Oklahoma 73112, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Dell Children's Medical Center of Central Texas
    Austin, Texas 78723, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Baylor College of Medicine and Texas Children's Hospital
    Houston, Texas 77030, United States
  • University of Texas Health Science Center at Tyler
    Tyler, Texas 75708, United States
  • University of Utah, Intermountain Cystic Fibrosis Center
    Salt Lake City, Utah 84132, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2020, 5 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2012
First posted
Dec 10, 2012
Start
Mar 2013
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Jan 13, 2020
Last update
Jan 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01746095
Lead sponsor
Savara Inc.
Collaborators
Synteract, Inc., Cystic Fibrosis Foundation
Responsible party
Sponsor
First posted
Dec 10, 2012
Start date
Mar 2013
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Jan 13, 2020
Last update
Jan 13, 2020

Study contacts

Elliott Dasenbrook, M.D., MHS
principal investigator · Case Western Reserve University School of Medicine and Rainbow Babies and Children's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion